论文信息 - Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC) - 字舞流文

Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)

M. Carducci | D. Petrylak | M. Doukas | R. Axelrod | D. Irwin | R. Bellet | M. Modiano | B. Kasimis | R. Mansour